Kathmandu, Jan. 29
Deurali Janta Pharmaceuticals Limited (DJPL) has
completed three decades in medicine production.
The first Nepali pharmaceutical company to implement the
WHO-standarised Good Manufacturing Practice is also the highest tax-paying
business from the sector, it said in a statement on Friday.
"We are at the forefront in terms of high corporate
social responsibility. DJPL has maintained the international standards in
medicine productions with the transfer of latest technology," said Hari
Bhakta Sharma, Executive Director of the company.
The company has independently producted various types of
medicines that are being used in the treatment of different diseases.
Currently, it is producing 330 types of medicinces, including capsule, tablet,
liquid, ointment and dry power.
DJPL has produces Favir-200 tablets, a medicine that is
used in the treatment of the coronavirus infection.
The medicine is under the clinical trial, implemented
jointly by the company, Health Ministry and Nepal Health Research Council.
The company claims that there is no negative impact of that
medicine so far. It has asked for the government approval to sell them in the
market.
DJPL has provided employment opportunities to some 500
people.
Published in The Rising Nepal daily on 30 January 2021.
No comments:
Post a Comment